Form 4: Elicio Therapeutics CSO Peter DeMuth Acquires Stock Options

Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, acquired stock options for 44,400 shares on February 3, 2025.

Summary

• Peter DeMuth, the Chief Scientific Officer of Elicio Therapeutics, acquired stock options on February 3, 2025.
• The options grant him the right to buy 44,400 shares of common stock at an exercise price of $8.92 per share.
• The options vest over a four-year period, starting with 25% vesting on February 3, 2026, and the remainder vesting monthly over the following three years, contingent upon continued service to Elicio Therapeutics.
• The expiration date for these options is February 3, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is neither particularly positive nor negative. It's a standard part of executive compensation.

Future Outlook

The vesting schedule incentivizes the Reporting Person's continued service to the Issuer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies.
• Vesting schedules, such as the one described, are designed to retain key personnel and incentivize long-term performance.
• The specific terms of the grant (number of shares, exercise price, vesting schedule) would need to be compared to similar grants at comparable companies to assess its relative value.

Stakeholder Impact

• The stock option grant aligns the interests of the Chief Scientific Officer with those of the shareholders.
• The vesting schedule incentivizes the executive to remain with the company, potentially benefiting employees and other stakeholders.

Key Dates